Phase I Clinical Trial of AZD2284, AZD2287, and AZD2275
/in Clinical Trial, Metastatic, Phase 1/by MaxBreaking Resistance: A Dual-Pathway Drug Shows Promise for Advanced Prostate Cancer
/in Preclinical Research/by MaxEnzalutamide Boosts PSA Control in High-Risk Prostate Cancer: Insights from the EMBARK Trial
/in Post-hoc, Retrospective studies/by MaxNewsletter 11/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Tired of this rain! Today’s update highlights three promising clinical trials alongside two intriguing preclinical studies. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it […]
Phase 1/2 trial: Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxFutureChem Launches Phase 3 Trial for Novel PSMA-Targeted Radiopharmaceutical FC705
/in Clinical Trial, Metastatic, Phase 3/by MaxEVM16: A Personalized mRNA Cancer Vaccine Enters Clinical Trials
/in Clinical Trial, Metastatic, Phase 1/by MaxNew Research Unlocks Potential for Immunotherapy in Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- CRISPR Advances June 16, 2026
- Turning Prostate Cancer from Cold to Hot: How Tiny Silica Particles Kill Tumors and Wake Up the Immune System June 16, 2026
- Killing the Last 0.1%: Targeting Cancer Persister Cells June 15, 2026
- Phase III PrTK03 Trial Results: Aglatimagene Besadenovec (CAN-2409) Improves Survival in Localized Prostate Cancer June 15, 2026